Secure Access Service Edge Market Innovations 2030, Technology Growth | Top Key Players Include Cisco Systems (US), HPE (US), Verizon (US), Broadcom (US), Fortinet (US)

“Cisco Systems (US), HPE (US), Verizon (US), Broadcom (US), Fortinet (US), Akamai (US), Oracle (US), Juniper Networks (US), Extreme Networks (US), AT&T (US), Palo Alto (US), Checkpoint Software Technologies (Israel), and Huawei (China).”
Secure Access Service Edge (SASE) Market by Offering (SD-WAN, SSE), SD-WAN offering (Software, Appliances), SSE offering (Zero Trust Network Access, Cloud Access Security Broker, Secure Web Gateway, Firewall as a Service) – Global Forecast to 2030.

The Secure Access Service Edge (SASE) market is projected to grow from USD 15.52 billion in 2025 to USD 44.68 billion by 2030, reflecting a compound annual growth rate (CAGR) of 23.6% during the forecast period. Modern SASE solutions increasingly leverage artificial intelligence (AI) and machine learning (ML) to enhance cybersecurity defenses against evolving threats. These technologies analyze network traffic to detect anomalies, such as unusual login attempts and irregular data transfers. By identifying threats early and reducing false positives, security teams can prioritize critical incidents and operate with greater efficiency. This proactive approach enables organizations to strengthen their security posture through intelligent, automated responses that maximize both protection and operational effectiveness.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=220384224

Cyber threats are becoming more advanced, persistent, and distributed across multiple entry points, making traditional standalone security tools ineffective. SASE provides a single cloud-based security approach that combines strong threat protection to block malware and unknown attacks, web traffic filtering to control and inspect outbound activity, and strict access enforcement based on user identity. It continuously verifies who the user is, the state of their device, and the situation in which access is requested. This ensures that access is never automatically trusted while also enabling faster detection of threats, better visibility across the network, and automated responses without disrupting the user experience.

By SD-WAN solution, the software segment is expected to hold a higher market share during the forecast period.

SD-WAN software provides companies the ability to administer and optimize their wide-area networks efficiently and with flexibility. The software centralizes control so administrators can establish policies for prioritized traffic, secure connections, and optimize application performance on various network paths. It dynamically routes traffic over broadband, MPLS, or LTE connections to maximize bandwidth while minimizing the usage of costly MPLS networks. It also features security elements such as encryption and firewall protection, delivering a secure and trustworthy network environment. With SD-WAN software, companies can scale their networks quickly, improve performance, and increase reliability, particularly in hybrid or remote work environments. It also provides real-time analytics and visibility into network performance, enabling companies to troubleshoot issues promptly and optimize traffic patterns. The software can easily integrate with cloud applications, providing smooth and unbroken performance. Due to this, organizations can achieve cost savings as well as enhanced user experiences throughout their whole network infrastructure.

By enterprise, the healthcare & life sciences segment is expected to hold the highest growth rate during the forecast period.

In the healthcare sector & life sciences, SASE is playing an important role in safeguarding digital transformation projects as companies increasingly rely on cloud infrastructure, remote employees, and connected healthcare technology. It safeguards sensitive patient data, facilitates compliance with industry regulations such as HIPAA and GDPR, and ensures that users, whether in hospitals, labs, homes, or on the move, can securely access the resources they need. Healthcare organizations benefit from SASE by having simplified management, pervasive security in distributed networks, and greater agility to roll out new applications and services. It streamlines the capability to enable telehealth, clinical research, and digital collaboration with low risk and enhanced operational effectiveness. As healthcare systems expand geographically and involve third-party collaborations, SASE also secures access to data and lowers vulnerabilities in collaborative processes to protect organizations from adapting cyber threats in spite of ever-evolving nature. Also, by integrating security and connectivity into one cloud native architecture, SASE reduces operational overhead and enables more rapid response to new compliance or patient care needs, which is critical in high-risk, data-intensive healthcare environments.

Asia Pacific region is projected to register the highest CAGR during the forecast period.

The Asia Pacific SASE market is growing at a rapid pace as countries embrace hybrid work patterns, expand cloud adoption, and spend on secure digital infrastructure. Digital transformation objectives drive the momentum in Japan, with the likes of Versa Networks and Cato Networks growing their footprint through new products and alliances. India is experiencing robust growth due to programs such as “Make in India” where Versa Networks, Tata Communications, and others are launching integrated SDWAN and cloud-native services in the primary industries. Hybrid work is thriving in Southeast Asia, particularly in Malaysia, Thailand, Vietnam, and the Philippines, and this has driven unmanaged device growth and cloud applications at more than 80% of organizations to favor single vendor configurations for added security and ease. Meanwhile, Australia and New Zealand prioritize integrated platforms in the public sector to enable remote staff and multi-cloud management. Across the region, surging demand for simplified, scalable, and secure networking drives the next generation of SASE adoption.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=220384224

Unique Features in the Secure Access Service Edge Market

SASE uniquely integrates wide-area networking (WAN) capabilities with comprehensive network security functions—including secure web gateways, cloud access security brokers (CASB), firewall-as-a-service (FWaaS), and zero trust network access (ZTNA)—into a single cloud-native platform. This convergence simplifies infrastructure, reduces latency, and supports consistent policy enforcement across all users and locations.

Unlike traditional perimeter-based security models, SASE operates with a cloud-first approach. Its distributed, scalable architecture enables seamless protection of users and devices regardless of their location, making it especially suitable for hybrid and remote work environments. This architecture ensures consistent performance and availability across global deployments.

SASE frameworks rely on user and device identity rather than IP addresses or location for access control. This identity-centric model supports granular, context-aware access decisions, ensuring users are only granted access to the specific resources they need, thereby enforcing zero trust principles.

Advanced SASE solutions utilize AI and ML to continuously analyze traffic patterns, user behaviors, and network anomalies. This enables real-time threat detection, minimizes false positives, and enhances the speed and accuracy of incident response. Predictive analytics also empower security teams to preemptively address vulnerabilities.

Major Highlights of the Secure Access Service Edge Market

Organizations are increasingly adopting zero trust models, and SASE plays a critical role in enabling this shift. By enforcing strict identity verification and least-privilege access policies, SASE supports a zero trust framework that aligns with modern security requirements.

As businesses transition to cloud-based operations and hybrid work environments, SASE provides a secure, scalable, and flexible framework to support distributed workforces. Its cloud-native design ensures consistent performance and security regardless of user location.

The use of artificial intelligence (AI) and machine learning (ML) in SASE solutions enhances threat detection, behavioral analytics, and automated responses. These intelligent capabilities significantly improve operational efficiency and threat mitigation efforts.

The need for centralized control and end-to-end visibility is a key driver in SASE adoption. Organizations benefit from unified dashboards that integrate networking and security metrics, simplifying policy management and improving incident response.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=220384224

Top Companies in the Secure Access Service Edge Market

The major vendors covered in SASE market include Cisco Systems (US), HPE (US), Verizon (US), Broadcom (US), Fortinet (US), Akamai (US), Oracle (US), Juniper Networks (US), Extreme Networks (US), AT&T (US), Palo Alto (US), Checkpoint Software Technologies (Israel), and Huawei (China). These players have incorporated various organic and inorganic growth strategies, including collaborations, acquisitions, product launches, partnerships, agreements, and expansions to strengthen their international footprint and capture a greater share of the SASE market. These organic and inorganic strategies have allowed the market players to expand across geographies by offering SASE infrastructure and services.

Cisco Systems

Cisco Systems is a global technology company specializing in networking, cybersecurity, collaboration, and cloud infrastructure, supporting enterprises, service providers, and the public sector with solutions that drive secure digital transformation. Its SD-WAN solution provides centralized branch connectivity, dynamic traffic routing, and integrated security with cloud compatibility and analytics. In SASE, Cisco provides a cloud-native platform that converges networking and security, with identity-based access, secure web gateways, firewall capabilities, and zero trust enforcement. In January 2024, Cisco and Kyndryl collaborated to co-create scalable security edge services, merging their SD-WAN capabilities to enable enterprises to create a strong roadmap for SASE adoption. The partnership aims to speed up secure cloud migrations while streamlining network management. Collectively, they want to provide end-to-end, flexible services that enable the IT needs of the modern enterprise.

Fortinet

Fortinet is a global cybersecurity company offering integrated, automated solutions designed to protect organizations of all sizes, including enterprises, governments, and service providers. Its portfolio spans firewalls, antivirus, intrusion prevention systems, and secure Wi-Fi, delivering end-to-end protection and visibility across networks. Fortinet’s SASE offering provides secure access to the internet, corporate resources, and SaaS applications through a unified platform powered by AI-driven security. It brings together a secure web gateway, zero trust network access, cloud access security broker, firewall-as-a-service, remote browser isolation, secure SD-WAN, and digital experience monitoring delivered through a single operating system and agent for streamlined management and consistent security across all users and locations. Its SD-WAN solution tightly integrates networking and security, allowing organizations to scale and modernize their infrastructure without compromising protection or performance.

Akamai Technologies

Akamai Technologies, Inc. is an American corporation specializing in content delivery networks (CDN), cybersecurity, DDoS protection, and cloud services. Among its enterprise products, Akamai offers a cloud-based zero-trust solution to give users secure, fast, and identity-aware access to private applications without using common VPNs. This solution grants app-level access based on user identity, context, and device posture, and supports both clientless and client-based access for web and non-web applications. It is designed to work seamlessly across multi-cloud and hybrid environments, integrates with identity providers and security information and event management (SIEM) tools, and enhances performance through Akamai’s global edge network and local points of presence. The architecture is designed for scalability and high availability, making deployment easier while enhancing security posture.

Hewlett Packard Enterprise (HPE)

Hewlett Packard Enterprise (HPE) has solidified its position in the Secure Access Service Edge (SASE) market through its HPE Aruba Networking division, offering a unified, AI-powered platform that integrates networking and security functionalities. Following the acquisition of Axis Security in 2023, HPE enhanced its Security Service Edge (SSE) capabilities—encompassing Zero Trust Network Access (ZTNA), Secure Web Gateway (SWG), Cloud Access Security Broker (CASB), and Digital Experience Monitoring (DEM)—to complement its EdgeConnect SD-WAN solutions. This integration enables organizations to deliver secure, seamless access to applications and data from any location, supporting hybrid work environments and cloud adoption. Recognized as a Leader in the 2024 GigaOm Radar Report for single-vendor SASE, HPE’s approach simplifies management, reduces costs, and enhances user experience by providing a comprehensive, edge-to-cloud security solution.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/secure-access-service-edge-market-220384224.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Secure Access Service Edge Market Innovations 2030, Technology Growth | Top Key Players Include Cisco Systems (US), HPE (US), Verizon (US), Broadcom (US), Fortinet (US)

Workplace Safety Market 2028 Future Trends, Emerging Growth, Applications and Driving Factors

“IBM (US), Honeywell (US), 3M (US), Hexagon AB (Sweden), Appian (US), Microsoft (US), Bosch (Germany), Cority (Canada), Wolters Kluwer (Netherland), Intelex (Canada), HCL Technologies (India), HIS (US), Vector Solutions (US), INX Software (Australia), Arventa (Australia).”
Workplace Safety Market by Component (Hardware, Software & Services), System (Real-Time Location Monitoring, Environmental Health & Safety, Access Control & Surveillance System), Application, Deployment Mode, End User and Region – Global Forecast to 2028.

The global workplace safety market is expected to expand significantly, rising from $15.7 billion in 2023 to $30.3 billion by 2028, reflecting a Compound Annual Growth Rate (CAGR) of 14.0% over the forecast period. This growth is largely driven by the growing emphasis on employee health and well-being, inspired by proactive frameworks such as NIOSH’s Total Worker Health initiative, which prioritizes preventive strategies and educational programs. Additionally, enforcement by regulatory bodies like OSHA and international organizations such as the ILO is accelerating the adoption of workplace safety solutions.

Companies are also increasingly investing in advanced technologies—such as IoT-based sensors and wearable devices—to enhance safety and efficiency. The rise of cloud computing, especially through software-as-a-service (SaaS) platforms, is further supporting this trend by offering scalable, cost-effective safety management solutions. Together, these factors are propelling sustained growth in the global workplace safety market.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=247399116

Concurrently, the increasing recognition of the significance of workplace safety is driving demand for innovative solutions. Employers are actively investing in IoT-enabled sensors and wearable devices, underscoring a commitment to employee well-being and operational efficiency. This heightened awareness aligns with emerging workplace safety trends, where a proactive shift prioritizes employee well-being to address the surge in work-related injuries. Furthermore, NIOSH’s Total Worker Health concept spearheads this transformative change, emphasizing prevention-focused programs and education to enhance overall workplace safety.

Based on the application, personal protective equipment detection is to grow at the highest CAGR during the forecasted period.

The exponential growth of personal protection equipment (PPE) detection in the workplace market is driven by an urgent need to enhance employee safety and compliance. PPE, encompassing safety helmets, gloves, eye protection, and more, acts as a crucial barrier against chemical, biological, and physical hazards. Detecting and managing PPE usage aids companies in ensuring compliance, which is particularly vital in high-risk environments such as chemical plants and laboratories. Instances of accidents caused by non-compliance underline the significance of regulations like the Personal Protective Equipment at Work Regulations in the UK in 1992. This legislation mandates employers to provide suitable PPE, fostering a workplace culture prioritizing health and safety. The burgeoning PPE detection market reflects a proactive shift towards mitigating workplace risks and safeguarding employee well-being.

By deployment mode, on-premises accounts for the highest market size during the forecast period.

The on-premises segment has the largest market size in the workplace safety market due to several key factors such as the security and data privacy concerns, especially prevalent in regulated industries like healthcare and finance, drive organizations to prioritize complete control over their data, mitigating risks associated with breaches or unauthorized access. Additionally, on-premises deployment provides unparalleled customization and integration capabilities with existing IT infrastructure, ensuring seamless alignment with specific organizational needs and workflows.

In locations with limited or unreliable internet connectivity, on-premises solutions offer a reliable alternative, ensuring accessibility and functionality even in challenging network conditions. Despite the higher initial costs, the long-term financial benefits, avoidance of ongoing subscription fees, and greater control over IT budgets contribute to the preference for on-premises solutions. Moreover, regulatory compliance requirements, particularly in certain industries, mandate on-premises data storage and management, further solidifying its dominance in the workplace safety market.

By region, Europe is to grow at the highest CAGR during the forecast period.

The European workplace safety market is witnessing unprecedented global growth, primarily propelled by a confluence of stringent regulations enforced rigorously by agencies like EU-OSHA, underscoring the region’s steadfast commitment to occupational health and safety, spurring continuous investments in cutting-edge safety solutions. The aging workforce’s susceptibility to health issues necessitates a targeted focus on ergonomic solutions, while the increasing adoption of automation fuels substantial investments in advanced technologies. The rising awareness among workers, fueled by media coverage and advocacy campaigns, prompts companies to respond with comprehensive safety training and innovative technologies.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=247399116

Unique Features in the Workplace Safety Market

One of the standout features of the modern workplace safety market is the adoption of cutting-edge technologies. From IoT-enabled sensors that monitor environmental conditions in real time to wearable devices that track worker health metrics, these innovations enhance situational awareness and incident prevention. This shift towards tech-driven solutions allows for proactive responses to potential hazards and supports data-driven safety strategies.

Inspired by frameworks such as NIOSH’s Total Worker Health, the market is increasingly shifting from reactive safety measures to preventive and holistic well-being approaches. Programs now focus not just on physical hazards, but also on mental health, stress management, ergonomics, and lifestyle-related factors that influence long-term employee health.

Stringent safety regulations from agencies like OSHA (Occupational Safety and Health Administration) and global organizations such as the International Labour Organization (ILO) are shaping the market. Compliance is not just a legal requirement—it has become a catalyst for companies to implement robust safety management systems, often driving innovation and investment in safety tools.

Cloud computing and Software-as-a-Service (SaaS) solutions have become game changers in workplace safety. These platforms allow companies to manage safety data, compliance records, training programs, and incident reports from centralized, scalable systems. The flexibility and cost-efficiency of SaaS models make them especially attractive to organizations seeking to modernize their safety infrastructure without heavy upfront investments.

Major Highlights of the Workplace Safety Market

Technological advancements are playing a central role in reshaping workplace safety. The integration of IoT devices, AI-based analytics, and wearable technologies enables real-time monitoring and predictive safety measures, significantly reducing the risk of workplace incidents and enabling faster response times.

Compliance with stringent regulations set by authorities such as OSHA and global organizations like the ILO continues to drive demand for comprehensive safety systems. These regulatory frameworks are pushing companies to adopt standardized safety practices and invest in compliance-supporting technologies and training.

There is a growing focus on preventive safety strategies and holistic employee well-being. Inspired by initiatives like NIOSH’s Total Worker Health, organizations are expanding their safety efforts to include mental health, ergonomics, and wellness programs—beyond traditional physical hazard prevention.

The adoption of cloud-based platforms and Software-as-a-Service (SaaS) models is a major highlight. These systems offer scalable, cost-effective, and easily deployable solutions for managing safety protocols, training, and compliance—particularly beneficial for organizations looking to modernize their safety operations.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=247399116

Top Companies in the Workplace Safety Market

IBM (US), Honeywell (US), 3M (US), Hexagon AB (Sweden), Appian (US), Microsoft (US), Bosch (Germany), Cority (Canada), Wolters Kluwer (Netherland), Intelex (Canada), HCL Technologies (India), HIS (US), Vector Solutions (US), INX Software (Australia), Arventa (Australia), AWS (US), Hitachi Solutions (Japan), Amotech (Canada), EHS Insight (US), EcoOnline (Norway), Guardhat (US), StrongArm Tech (US), Kinetic JS), ANVL (US), Intenseye (US) are the key players and other players in the workplace safety market.

IBM (US):

IBM offers Watson Safety solutions that leverage AI and analytics to improve workplace safety by predicting and preventing incidents, identifying hazards, and ensuring compliance with regulations.

Honeywell (US):

Honeywell provides a range of safety solutions, including personal protective equipment (PPE), gas detection systems, and industrial automation technologies, aimed at enhancing workplace safety and productivity.

3M (US):

3M manufactures a variety of safety products such as respirators, earplugs, safety glasses, and fall protection equipment, helping workers stay safe in diverse industrial environments.

Hexagon AB (Sweden):

Hexagon offers workplace safety solutions through its Safety & Infrastructure division, providing software for incident management, emergency response, and risk analysis to ensure a safe working environment.

Appian (US):

Appian’s low-code automation platform enables organizations to streamline safety processes, automate workflows, and manage incidents effectively, ensuring compliance with safety regulations and standards.

Microsoft (US):

Microsoft offers workplace safety solutions through its Azure cloud platform, leveraging IoT, AI, and data analytics to monitor environmental conditions, detect hazards, and improve overall safety performance.

Bosch (Germany):

Bosch provides a range of safety technologies for industrial and commercial applications, including video surveillance, access control systems, and emergency communication solutions, enhancing workplace safety and security.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/workplace-safety-market-247399116.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Workplace Safety Market 2028 Future Trends, Emerging Growth, Applications and Driving Factors

Heritage Bridge Genealogy Unveils Family Legacy Service to Help Families Preserve Their Ancestral Roots

New offering supports individuals seeking to create a lasting historical record of their family lineage

Columbus, OH – May 9, 2025 – Heritage Bridge Genealogy, a trusted provider of professional genealogy services, is proud to announce the launch of its Family Legacy Service. This newly introduced offering is tailored for busy individuals who want to create their family tree and preserve their family’s story for future generations but lack the time or expertise to complete the research themselves.

Ancestral Research for Modern Families

The Family Legacy Service enables clients to trace their American ancestry back to their great-grandparents, encompassing seven ancestral couples. Each project is conducted by a professional genealogist who delivers a detailed report that includes vital records, census data, church documents, land deeds, and historical newspaper accounts. These resources combine to offer a well-rounded and personal look at each ancestor’s life and time.

“Our goal is to help families keep their heritage alive,” said Laurie Hermance-Moore, owner of Heritage Bridge Genealogy. “The stories we uncover are more than names and dates—they reflect the resilience, challenges, and accomplishments of past generations.”

Personal Attention and Historical Depth

Unlike larger firms, Heritage Bridge is a boutique agency made up of seven experienced genealogists. Clients work directly with a dedicated researcher throughout the process, ensuring each report is customized and accurate. This focused approach allows for a deeper, more meaningful exploration of family history.

Clients can also choose to transform their findings into keepsakes such as heirloom-quality books or professionally designed family trees. These options help families not only create my family tree but also share it with relatives in a lasting and engaging format. If desired, families can submit photos to be included in the report.

Learn more about family legacy service at https://www.heritagebridge.com/family-legacy.

About Heritage Bridge Genealogy

Based in Columbus, Ohio, Heritage Bridge Genealogy offers professional genealogy services to clients across the United States. The agency specializes in historical storytelling and personalized research, helping families uncover and preserve their unique legacies.

Media Contact
Company Name: Heritage Bridge Genealogy
Contact Person: Laurie Hermance-Moore, Accredited Genealogist®
Email: Send Email
Country: United States
Website: https://www.heritagebridge.com/

Lymphangioleiomyomatosis Market Revenue to Expand Significantly by 2032, States DelveInsight Report | Novartis, Children’s Hospital Medical Center, Cincinnati

The Key Lymphangioleiomyomatosis Companies in the market include – Novartis, Children’s Hospital Medical Center, Cincinnati, and others.

 

DelveInsight’s “Lymphangioleiomyomatosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Lymphangioleiomyomatosis, historical and forecasted epidemiology as well as the Lymphangioleiomyomatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Lymphangioleiomyomatosis, offering comprehensive insights into the Lymphangioleiomyomatosis revenue trends, prevalence, and treatment landscape. The report delves into key Lymphangioleiomyomatosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Lymphangioleiomyomatosis therapies. Additionally, we cover the landscape of Lymphangioleiomyomatosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Lymphangioleiomyomatosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Lymphangioleiomyomatosis space.

 

To Know in detail about the Lymphangioleiomyomatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lymphangioleiomyomatosis Market Forecast

 

Some of the key facts of the Lymphangioleiomyomatosis Market Report:

  • The Lymphangioleiomyomatosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • Key Lymphangioleiomyomatosis Companies: Novartis, Children’s Hospital Medical Center, Cincinnati, and others

  • Key Lymphangioleiomyomatosis Therapies: Everolimus (RAD001), RAD001, and others

  • The Lymphangioleiomyomatosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lymphangioleiomyomatosis pipeline products will significantly revolutionize the Lymphangioleiomyomatosis market dynamics.

  • Rare disease, primarily affecting women of childbearing age, typically between 20 and 40 years old

  • The estimated prevalence of LAM is approximately 3–8 cases per million women worldwide

  • LAM can occur sporadically (sporadic LAM) or in association with tuberous sclerosis complex (TSC-LAM)

  • Sporadic LAM accounts for about 80–90% of all LAM cases

  • TSC-LAM is observed in around 30–40% of women with tuberous sclerosis complex

 

Lymphangioleiomyomatosis Overview

Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that primarily affects women, usually during their childbearing years. It is characterized by the abnormal growth of smooth muscle-like cells in the lungs, lymphatic system, and kidneys, leading to lung cysts, airway obstruction, and respiratory issues. Over time, LAM can cause breathing difficulties, lung collapse (pneumothorax), and reduced lung function. It can occur sporadically or in association with a genetic condition called tuberous sclerosis complex (TSC).

 

Get a Free sample for the Lymphangioleiomyomatosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/lymphangioleiomyomatosis-market

 

Lymphangioleiomyomatosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Lymphangioleiomyomatosis Epidemiology Segmentation:

The Lymphangioleiomyomatosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Lymphangioleiomyomatosis

  • Prevalent Cases of Lymphangioleiomyomatosis by severity

  • Gender-specific Prevalence of Lymphangioleiomyomatosis

  • Diagnosed Cases of Episodic and Chronic Lymphangioleiomyomatosis

 

Download the report to understand which factors are driving Lymphangioleiomyomatosis epidemiology trends @ Lymphangioleiomyomatosis Epidemiology Forecast

 

Lymphangioleiomyomatosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lymphangioleiomyomatosis market or expected to get launched during the study period. The analysis covers Lymphangioleiomyomatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Lymphangioleiomyomatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Lymphangioleiomyomatosis Therapies and Key Companies

  • Everolimus (RAD001): Novartis

  • RAD001: Children’s Hospital Medical Center, Cincinnati

 

Discover more about therapies set to grab major Lymphangioleiomyomatosis market share @ Lymphangioleiomyomatosis Treatment Landscape

 

Lymphangioleiomyomatosis Market Drivers

  • Increased awareness and early diagnosis of rare diseases including LAM through patient advocacy and physician education

  • Advancements in genetic research and identification of TSC mutations linked to LAM have enhanced diagnostic accuracy

  • Emerging targeted therapies such as mTOR inhibitors (e.g., sirolimus) have shown promising results in managing symptoms and slowing disease progression

  • Supportive regulatory frameworks (e.g., Orphan Drug Designation) encourage the development of treatments for rare diseases like LAM

 

Lymphangioleiomyomatosis Market Barriers

  • Low disease prevalence limits commercial interest and investment from major pharmaceutical companies

  • Delayed diagnosis due to nonspecific symptoms often misdiagnosed as asthma or COPD

  • Limited treatment options currently available, with no definitive cure for the disease

  • High cost of therapy and long-term care poses economic challenges for both patients and healthcare systems

  • Lack of large-scale clinical trials due to difficulty in recruiting sufficient patient populations for a rare condition

 

Scope of the Lymphangioleiomyomatosis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Lymphangioleiomyomatosis Companies: Novartis, Children’s Hospital Medical Center, Cincinnati, and others

  • Key Lymphangioleiomyomatosis Therapies: Everolimus (RAD001), RAD001, and others

  • Lymphangioleiomyomatosis Therapeutic Assessment: Lymphangioleiomyomatosis current marketed and Lymphangioleiomyomatosis emerging therapies

  • Lymphangioleiomyomatosis Market Dynamics: Lymphangioleiomyomatosis market drivers and Lymphangioleiomyomatosis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Lymphangioleiomyomatosis Unmet Needs, KOL’s views, Analyst’s views, Lymphangioleiomyomatosis Market Access and Reimbursement

 

To know more about Lymphangioleiomyomatosis companies working in the treatment market, visit @ Lymphangioleiomyomatosis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Lymphangioleiomyomatosis Market Report Introduction

2. Executive Summary for Lymphangioleiomyomatosis

3. SWOT analysis of Lymphangioleiomyomatosis

4. Lymphangioleiomyomatosis Patient Share (%) Overview at a Glance

5. Lymphangioleiomyomatosis Market Overview at a Glance

6. Lymphangioleiomyomatosis Disease Background and Overview

7. Lymphangioleiomyomatosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Lymphangioleiomyomatosis

9. Lymphangioleiomyomatosis Current Treatment and Medical Practices

10. Lymphangioleiomyomatosis Unmet Needs

11. Lymphangioleiomyomatosis Emerging Therapies

12. Lymphangioleiomyomatosis Market Outlook

13. Country-Wise Lymphangioleiomyomatosis Market Analysis (2019–2032)

14. Lymphangioleiomyomatosis Market Access and Reimbursement of Therapies

15. Lymphangioleiomyomatosis Market Drivers

16. Lymphangioleiomyomatosis Market Barriers

17. Lymphangioleiomyomatosis Appendix

18. Lymphangioleiomyomatosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lymphangioleiomyomatosis Market Revenue to Expand Significantly by 2032, States DelveInsight Report | Novartis, Children’s Hospital Medical Center, Cincinnati

Acute Respiratory Distress Syndrome Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | RS BioTherapeutics, AVM Biotech, Cynata Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Respiratory Distress Syndrome pipeline constitutes 50+ key companies continuously working towards developing 50+ Acute Respiratory Distress Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

The Acute Respiratory Distress Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Acute Respiratory Distress Syndrome Pipeline Insight, 2025 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome Market.

 

Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Acute Respiratory Distress Syndrome treatment therapies with a considerable amount of success over the years.

  • Acute Respiratory Distress Syndrome companies working in the treatment market are RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompé Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy’s and St Thomas’ NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others, are developing therapies for the Acute Respiratory Distress Syndrome treatment

  • Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others are expected to have a significant impact on the Acute Respiratory Distress Syndrome market in the coming years.

  • In February 2025, Bonus Biogroup (TASE: BONS), a late-stage biotech firm specializing in immunomodulatory and regenerative mesenchymal stromal cell (MSC) therapies, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase III clinical trial in the U.S. The study will assess the safety and effectiveness of MesenCure™—an allogeneic cell therapy composed of enhanced MSCs derived from adipose tissue—for the treatment of respiratory distress in severely ill, hospitalized patients suffering from COVID-19-related pneumonia. MesenCure is designed to address inflammation and tissue damage.

  • In January 2025, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapies targeting the complement system, has announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab). This approval covers the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard care and require invasive mechanical ventilation (IMV), with or without extracorporeal membrane oxygenation (ECMO). GOHIBIC is the first and only approved therapy in the EU specifically for SARS-CoV-2-related ARDS.

  • In November 2024, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm specializing in anti-inflammatory treatments targeting the complement system, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the marketing authorization of GOHIBIC (vilobelimab). The recommendation supports its use under exceptional circumstances for adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids and invasive mechanical ventilation (IMV), with or without ECMO. The company anticipates a final decision from the European Commission within 67 days.

  • In October 2024, BioAegis Therapeutics, an innovative biotech company focused on developing therapies for inflammatory diseases, is excited to announce the enrollment of the first patient in its Phase 2 study of rhu-pGSN for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955).

 

Acute Respiratory Distress Syndrome Overview

Acute Respiratory Distress Syndrome (ARDS) is a severe condition in which the lungs become inflamed and fill with fluid, leading to difficulty breathing and low oxygen levels in the blood. It can result from various causes, including infections, trauma, pneumonia, or inhalation of harmful substances. Symptoms include shortness of breath, rapid breathing, and low oxygen levels. ARDS is a medical emergency that often requires hospitalization, with treatments including oxygen therapy, mechanical ventilation, and addressing the underlying cause. In severe cases, ARDS can lead to organ failure and may be life-threatening.

 

Get a Free Sample PDF Report to know more about Acute Respiratory Distress Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight

 

Emerging Acute Respiratory Distress Syndrome Drugs Under Different Phases of Clinical Development Include:

  • RSBT-001: RS BioTherapeutics

  • AVM0703: AVM Biotechnology

  • CYP 001: Cynata Therapeutics

  • AV 001: Vasomune Therapeutics

  • ALT-100: Aqualung Therapeutics

  • STSA-1002: Staidson (Beijing) Biopharmaceuticals

  • GEn-1124: GEn1E Lifesciences

  • Descartes 30: Cartesian Therapeutics

  • Rhu-pGSN: BioAegis Therapeutics Inc.

  • ExoFlo: Direct Biologics, LLC

  • Reparixin 600mg: Dompé Farmaceutici S.p.A

  • Centhaquine: Pharmazz, Inc.

  • ALT-100 mAb: Aqualung Therapeutics Corp.

  • MRG-001: MedRegen LLC

  • TTI-0102: Thiogenesis Therapeutics, Inc.

  • Dexamethasone: Hospital Universitario Infanta Leonor

  • Isoflurane: Guy’s and St Thomas’ NHS Foundation Trust

  • Pirfenidone/Placebo: Fujian Medical University

  • Trimodulin: Biotest

  • AeroFact: Aerogen Pharma Limited

  • Ibudilast: MediciNova

  • Poractant Alfa: NorthShore University HealthSystem

  • Tozorakimab: AstraZeneca

  • L-citrulline: Asklepion Pharmaceuticals

 

Acute Respiratory Distress Syndrome Route of Administration

Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

  • Molecule Type

 

Acute Respiratory Distress Syndrome Molecule Type

Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

 

Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment

  • Acute Respiratory Distress Syndrome Assessment by Product Type

  • Acute Respiratory Distress Syndrome By Stage and Product Type

  • Acute Respiratory Distress Syndrome Assessment by Route of Administration

  • Acute Respiratory Distress Syndrome By Stage and Route of Administration

  • Acute Respiratory Distress Syndrome Assessment by Molecule Type

  • Acute Respiratory Distress Syndrome by Stage and Molecule Type

 

DelveInsight’s Acute Respiratory Distress Syndrome Report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Acute Respiratory Distress Syndrome product details are provided in the report. Download the Acute Respiratory Distress Syndrome pipeline report to learn more about the emerging Acute Respiratory Distress Syndrome therapies

 

Some of the key companies in the Acute Respiratory Distress Syndrome Therapeutics Market include:

Key companies developing therapies for Acute Respiratory Distress Syndrome are – Fisher & Paykel Healthcare Limited, NRx Pharmaceuticals, Inc., Faron Pharmaceuticals, BioMarck Pharmaceuticals, GE Healthcare, Hamilton Company, Athersys, United Therapeutics, Apeptico Forschung, HEALIOS K.K, Dragerwerk AG & Co. KGaA, ALung Technologies, Inc ( LivaNova PLC), and others.

 

Acute Respiratory Distress Syndrome Pipeline Analysis:

The Acute Respiratory Distress Syndrome pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Acute Respiratory Distress Syndrome with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Respiratory Distress Syndrome Treatment.

  • Acute Respiratory Distress Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Acute Respiratory Distress Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Respiratory Distress Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Acute Respiratory Distress Syndrome drugs and therapies

 

Acute Respiratory Distress Syndrome Pipeline Market Drivers

  • Rising incidence of Acute Respiratory Distress Syndrome, the rising geriatric population are some of the important factors that are fueling the Acute Respiratory Distress Syndrome Market.

 

Acute Respiratory Distress Syndrome Pipeline Market Barriers

  • However, increasing Cost of Treatment Therapeutics, lack of Skilled Professionals and other factors are creating obstacles in the Acute Respiratory Distress Syndrome Market growth.

 

Scope of Acute Respiratory Distress Syndrome Pipeline Drug Insight

  • Coverage: Global

  • Key Acute Respiratory Distress Syndrome Companies: RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompé Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy’s and St Thomas’ NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others

  • Key Acute Respiratory Distress Syndrome Therapies: RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others

  • Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies

  • Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers

 

Request for Sample PDF Report for Acute Respiratory Distress Syndrome Pipeline Assessment and clinical trials

 

Table of Contents

1. Acute Respiratory Distress Syndrome Report Introduction

2. Acute Respiratory Distress Syndrome Executive Summary

3. Acute Respiratory Distress Syndrome Overview

4. Acute Respiratory Distress Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Acute Respiratory Distress Syndrome Pipeline Therapeutics

6. Acute Respiratory Distress Syndrome Late Stage Products (Phase II/III)

7. Acute Respiratory Distress Syndrome Mid Stage Products (Phase II)

8. Acute Respiratory Distress Syndrome Early Stage Products (Phase I)

9. Acute Respiratory Distress Syndrome Preclinical Stage Products

10. Acute Respiratory Distress Syndrome Therapeutics Assessment

11. Acute Respiratory Distress Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Respiratory Distress Syndrome Key Companies

14. Acute Respiratory Distress Syndrome Key Products

15. Acute Respiratory Distress Syndrome Unmet Needs

16 . Acute Respiratory Distress Syndrome Market Drivers and Barriers

17. Acute Respiratory Distress Syndrome Future Perspectives and Conclusion

18. Acute Respiratory Distress Syndrome Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Respiratory Distress Syndrome Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | RS BioTherapeutics, AVM Biotech, Cynata Therapeutics

Craft Pavers Sealing: Revolutionizing Florida’s Paver Sealing Market with Transparent Pricing & Unmatched Value

Craft Pavers Sealing eliminates the guesswork from pricing with its interactive map tool, allowing homeowners to outline their project area and receive an instant cost estimate. Starting at just $1.25 per square foot, the company provides one of the most competitive rates in the market while ensuring top-tier service.

Boca Raton, Florida – May 9, 2025 – Florida homeowners seeking professional paver sealing services now have a clear, cost-effective solution thanks to Craft Pavers Sealing, a leader in the industry with a commitment to affordability, transparency, and quality. The company confidently asserts that it offers the best paver sealing prices in Florida, backed by an innovative pricing model and a comprehensive service package designed to protect and enhance outdoor living spaces.

Transparent Pricing with an Interactive Estimating Tool

Craft Pavers Sealing eliminates the guesswork from pricing with its interactive map tool, allowing homeowners to outline their project area and receive an instant cost estimate. Starting at just $1.25 per square foot, the company provides one of the most competitive rates in the market while ensuring top-tier service.

Three Simple Pricing Tiers Based on Project Size:

Small Projects (Up to 1,000 sq ft) – Ideal for patios, walkways, and small pool decks.

Medium Projects (1,000 – 2,500 sq ft) – Perfect for driveways and larger outdoor spaces.

Large Projects (2,500+ sq ft) – Tailored for expansive residential and commercial properties.

Each tier includes essential services such as pre-wash treatment, joint cleaning, surface cleaning, premium sealer application, and re-sanding joints, ensuring a thorough and long-lasting finish.

Comprehensive Service for Lasting Protection

Florida’s harsh climate—intense sun, heavy rain, and high humidity—demands durable paver protection. Craft Pavers Sealing delivers with a full-service approach, including:

• Mold, mildew, and stain removal

• High-pressure cleaning

• Premium sealer application (sprayed flood coat method)

• Joint re-sanding for stability

• Back-rolling for even coverage

Optional add-ons, such as stripping old sealer, paver repairs, and colored sand application, allow for customization based on specific needs.

Why Professional Paver Sealing is a Smart Investment

Beyond aesthetics, professional sealing:

• Extends paver lifespan by 5-10 years

• Prevents costly erosion and water damage

• Resists UV fading and stains

• Reduces long-term maintenance costs

• Boosts curb appeal and property value

Customer Confidence: Warranty, Free Estimates & Satisfaction Guarantee

Craft Pavers Sealing stands behind its work with a 100% satisfaction guarantee and warranty, ensuring peace of mind for every customer. Homeowners can also take advantage of free estimates and browse a gallery of completed projects to see the quality firsthand.

Get Your Personalized Quote Today

For Florida homeowners ready to protect their pavers at the best price in the state, Craft Pavers Sealing offers multiple ways to get started:

Media Contact
Company Name: Craft Pavers Sealing & Restoration
Contact Person: Ciprian Stancioi
Email: Send Email
Phone: (954) 478-4674
Country: United States
Website: https://craft-pavers.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Craft Pavers Sealing: Revolutionizing Florida’s Paver Sealing Market with Transparent Pricing & Unmatched Value

Gujarat Science City Celebrates World Penguin Day With Special Announcement And The Birth Of Three African Penguin Chicks

Gujarat Science City celebrates World Penguin Day with the historic birth of three African Penguin chicks—Daisy, Kiara, and Balloo—highlighting a milestone in marine conservation.

On the occasion of World Penguin Day, Gujarat Science City is delighted to celebrate a significant milestone — the successful in-house breeding of three African Penguin chicks at the Aquatic Gallery. This marks a historic achievement in the Gallery’s ongoing commitment to conservation, education, and marine biodiversity.

To commemorate this special day, Gujarat Science City proudly announces the names of the three newly born penguin chicks: Daisy, Kiara, and Balloo. These names were carefully chosen to reflect joy, affection, and the growing public connection with the penguin family.

The successful breeding programme, led by the expert Husbandry Team at the Aquatic Gallery, began in June 2024 with the first egg laid and hatched in July after a 38-day incubation. In a rare and heartening development, the penguin pair laid a second clutch of two eggs in October, which hatched in November — resulting in two female chicks and one male chick.

This accomplishment is the result of a specially designed nesting environment that mimics the penguins’ natural habitat, providing safety, privacy, and optimal breeding conditions. In addition, the penguins were supported with a carefully curated feeding and enrichment programme during the mating and chick-rearing period.

The African Penguin (Spheniscus demersus), native to the coasts of South Africa and Namibia, is listed as Critically Endangered by the IUCN. With fewer than 19,800 mature individuals remaining in the wild, successful captive breeding plays a vital role in global conservation efforts.

Speaking on the occasion, Ms. Mona K. Khandhar, IAS, Principal Secretary, Department of Science & Technology, Government of Gujarat, said,

“The birth of these penguin chicks is a proud moment not only for Gujarat Science City but for the entire state. It reflects our dedication to animal welfare, conservation, and science education. We invite citizens and visitors to meet Daisy, Kiara, and Balloo — our new ambassadors for marine conservation.”

The penguin exhibit is now open for visitors, offering an exciting and educational experience for all age groups. This World Penguin Day, let us renew our commitment to protecting endangered species and preserving our planet’s marine ecosystems.

Media Contact
Company Name: Gujarat Science City
Contact Person: Jalpa Dave
Email: Send Email
City: New Delhi
State: Delhi
Country: India
Website: https://sciencecity.gujarat.gov.in/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gujarat Science City Celebrates World Penguin Day With Special Announcement And The Birth Of Three African Penguin Chicks

Tivano Cutting Board Review: Must Read This Before Buying

If you’ve ever dealt with smelly, stained, or warped cutting boards, you’re not alone. Traditional boards, whether wooden or plastic, often fall short in terms of cleanliness and durability. That’s where the Tivano Cutting Board steps in to completely change how you approach food prep. Designed with advanced materials and smart hygiene features, this board offers both functionality and peace of mind in the kitchen.

At the heart of Tivano’s innovation is its TitaniumShield surface a sleek, non porous layer that doesn’t absorb moisture or odors. Unlike wood, which can crack and trap bacteria, or plastic, which can develop deep cuts that harbor germs, this titanium surface resists both. It’s incredibly easy to wipe clean and doesn’t retain smells, even from pungent foods like garlic or onions.

The build quality is also impressive. It’s scratch resistant, so even with heavy daily use, it maintains its sleek look without deep gouges. And unlike boards that warp after multiple washes or temperature changes, Tivano holds its shape reliably over time.

One often overlooked feature in a cutting board is its impact on your kitchen knives. The Tivano board strikes a smart balance: it’s firm enough to provide a stable surface for chopping but engineered to reduce wear on knife blades. This helps maintain the sharpness of your knives longer, which means more precise cuts and less frequent sharpening sessions.

Cleaning the Tivano Cutting Board is a breeze. Its non stick, non absorbent surface doesn’t trap food residue, which makes rinsing or wiping it down quick and effective. It’s also dishwasher safe, which is a bonus for busy households or anyone who wants to ensure a thorough clean with minimal effort. Unlike wood boards that need regular oiling and plastic boards that stain easily, Tivano is virtually maintenance free.

Hygiene is one of the standout features of this product. The antibacterial properties of the TitaniumShield™ surface help prevent the growth of harmful bacteria like E. coli and Salmonella. For anyone who prepares raw meat, seafood, or poultry, this board adds an extra layer of protection in preventing cross contamination. Its liquid resistant surface keeps juices from seeping in, making it safer and more sanitary compared to traditional cutting boards.

Real world users are genuinely pleased with the performance of the Tivano Cutting Board. Many note how it doesn’t carry over odors between uses and keeps their kitchen environment cleaner and fresher. Some also mention how their knives stay sharper for longer, a testament to the board’s blade friendly design. With overwhelmingly positive reviews and a near perfect customer satisfaction score, it’s clear this board delivers on its promises.

The Tivano Cutting Board is more than just a surface to chop vegetables or slice meat. It’s a thoughtful solution to the hygiene and durability issues that plague many kitchen cutting boards. With its antibacterial properties, premium titanium coating, and knife safe surface, it provides long term value and confidence for any home cook.

If you’re looking for a cutting board that looks modern, performs exceptionally, and contributes to a healthier kitchen environment, the Tivano Cutting Board is definitely worth considering.

Media Contact
Company Name: News Zone
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://rebrand.ly/ultracuttingboard

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tivano Cutting Board Review: Must Read This Before Buying

Primary Biliary Cholangitis Treatment Market Valued at USD 1.2 Billion in 2023; Projected to Grow Significantly Through 2034 Driven by Anticipated Pipeline Drugs | DelveInsight

“Primary Biliary Cholangitis Market Insight, Epidemiology, and Market Forecast – 2034”
The primary biliary cholangitis treatment market is experiencing significant growth, driven by an increasing prevalence of the disease, improved diagnostic capabilities, and the introduction of new therapeutic options by key companies including Gilead Sciences, Intercept Pharmaceuticals, CymaBay Therapeutics, COUR Pharmaceuticals, Teva Pharmaceutical, Mylan, AbbVie, Glenmark Pharmaceuticals, and Allergan. These companies are actively working to meet the substantial unmet needs in this area.

DelveInsight’s “Primary Biliary Cholangitis Market Insight, Epidemiology, and Market Forecast – 2034” report delivers comprehensive insights into the PBC market, including historical and forecasted epidemiology as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.

The primary biliary cholangitis market size was USD 1.2 billion across the 7MM in 2023, which is forecasted to increase steadily from 2024 to 2034. Furthermore, the US accounted for the largest PBC market share. This trend is expected to continue in the forecasted period, due to a larger patient pool, better disease awareness, and favourable reimbursement policies.

Download the Primary Biliary Cholangitis Market Forecast Report to understand which factors are driving the Primary Biliary Cholangitis market @ Primary Biliary Cholangitis Market Trends.

The report provides detailed epidemiological data segmentation covering total diagnosed prevalent cases, gender-specific diagnosed prevalent cases, and age-specific diagnosed prevalent cases of primary biliary cholangitis across the 7MM during the study period (2020-2034).

According to the primary biliary cholangitis epidemiology contained in the report, the US accounted for the largest proportion of diagnosed prevalent PBC cases among the 7MM in 2023. Furthermore, the epidemiology model reveals a significantly higher prevalence among females compared to males across all markets, attributable to genetic predisposition, hormonal influences, and environmental factors. Among European nations, Germany reported the highest burden, followed by Italy and the UK. The data also indicates that PBC predominantly affects individuals aged 40-70 years, reinforcing the importance of age-targeted screening and treatment strategies.

Discover evolving trends in the Primary Biliary Cholangitis patient pool forecasts @ Primary Biliary Cholangitis Epidemiological Analysis.

The current primary biliary cholangitis treatment landscape has been historically dominated by ursodeoxycholic acid (UDCA) as the cornerstone first-line therapy, with obeticholic acid (OCALIVA) from Intercept Pharmaceuticals serving as the second-line option for patients with inadequate response to or intolerance of UDCA. However, the therapeutic paradigm has experienced significant evolution in 2024 with the FDA granting accelerated approvals to two novel treatments: Elafibranor (IQIRVO) in June 2024 by Genfit/Ipsen and Seladelpar (LIVDELZI) in August 2024 by Gilead Sciences. Both therapeutics represent innovative approaches targeting peroxisome proliferator-activated receptors, offering new mechanisms to address the complex primary biliary cholangitis pathophysiology.

The primary biliary cholangitis clinical trials market is demonstrating robust activity, with several promising candidates advancing through the development pipeline. Saroglitazar Magnesium by Zydus Therapeutics, a dual PPAR alpha/gamma agonist with the FDA Fast Track and Orphan Drug designations, shows substantial potential in addressing both cholestasis and metabolic aspects of PBC. A Phase IIb/III trial (NCT05133336) is ongoing to further evaluate its dual PPAR alpha/gamma agonism targeting metabolic and inflammatory pathways.

GlaxoSmithKline’s Linerixibat, an IBAT inhibitor currently in Phase III trials, targets the debilitating pruritus associated with PBC. Additionally, COUR Pharmaceuticals’ CNP-104 secured FDA Orphan Drug Designation in January 2025, positioning it as potentially the first disease-modifying treatment for PBC by inducing tolerance to pathogenic activated PDC-E2 T-cells that drive bile duct inflammation.

Discover evolving trends in the Primary Biliary Cholangitis treatment landscape @ Primary Biliary Cholangitis Recent Developments.

Despite these significant advancements, the PBC market faces several challenges, including insufficient disease awareness among healthcare providers and patients, complex diagnostic processes resulting in under-recognition, and affordability barriers to innovative treatments. Addressing these obstacles will require comprehensive educational initiatives, streamlined diagnostic pathways, and creative pricing strategies to improve treatment accessibility.

Furthermore, safety concerns continue to emerge, as evidenced by the FDA’s recent identification of serious liver injury cases in non-cirrhotic PBC patients treated with obeticholic acid. This new safety concern was announced in a Drug Safety Communication in December 2024, following a review of postmarket clinical trial data, highlighting the ongoing need for vigilant safety monitoring of both established and emerging therapies.

The primary biliary cholangitis competitive landscape is evolving rapidly, with several key players actively involved in therapeutic development and commercialization. Some of the pharmaceutical companies active in this landscape include Gilead Sciences (NASDAQ: GILD), Intercept Pharmaceuticals (NASDAQ: ICPT), CymaBay Therapeutics (NASDAQ: CBAY), COUR Pharmaceuticals, Teva Pharmaceutical (NYSE: TEVA), Mylan, AbbVie (NYSE: ABBV), Glenmark Pharmaceuticals (NSE: GLENMARK), Allergan, Eli Lilly (NYSE: LLY), Novartis (NYSE: NVS), Pfizer (NYSE: PFE), Roche (SWX: ROG), Merck (NYSE: MRK), Bristol-Myers Squibb (NYSE: BMY), AstraZeneca (NASDAQ: AZN), GlaxoSmithKline (NYSE: GSK), Takeda (NYSE: TAK), Amgen (NASDAQ: AMGN), Boehringer Ingelheim, Dr. Reddy’s (NYSE: RDY), Amneal (NASDAQ: AMRX), Alnylam (NASDAQ: ALNY), Ionis (NASDAQ: IONS), Arrowhead (NASDAQ: ARWR), CureVac (NASDAQ: CVAC), Sangamo (NASDAQ: SGMO), Calliditas Therapeutics (NASDAQ: CALT), NGM Biopharmaceuticals (NASDAQ: NGM), Bluebird Bio (NASDAQ: BLUE), Intellia (NASDAQ: NTLA), Albireo, TARGET PharmaSolutions, Genfit (NASDAQ: GNFT), and Ascletis Pharma, among others.

Looking ahead, DelveInsight forecasts the primary biliary cholangitis market will witness accelerated growth driven by the continued uptake of newly approved therapies and the potential introduction of pipeline candidates addressing unmet needs. The integration of biomarker-guided treatment approaches and combination regimens is anticipated to optimize therapeutic outcomes, while ongoing research into disease-modifying interventions may fundamentally transform the treatment paradigm. As the understanding of PBC pathophysiology advances, the market is poised for further innovation, with the ultimate goal of improving quality of life and long-term outcomes for patients living with this challenging autoimmune liver condition.

Table of Contents

1. Key Insights

2. Executive Summary of Primary Biliary Cholangitis

3. Primary Biliary Cholangitis Competitive Intelligence

4. Primary Biliary Cholangitis: Market Overview at a Glance

5. Primary Biliary Cholangitis: Disease Background and Overview

6. Patient Journey

7. Primary Biliary Cholangitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Primary Biliary Cholangitis Unmet Needs

10. Key Endpoints of Primary Biliary Cholangitis Treatment

11. Primary Biliary Cholangitis Marketed Products

12. Primary Biliary Cholangitis Emerging Therapies

13. Primary Biliary Cholangitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Primary Biliary Cholangitis

17. KOL Views

18. Primary Biliary Cholangitis Market Drivers

19. Primary Biliary Cholangitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports

Primary Biliary Cholangitis Pipeline Insight

Primary Biliary Cholangitis Pipeline Insight provides comprehensive insights about the Primary Biliary Cholangitis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Primary Biliary Cholangitis companies, including Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Calliditas Therapeutics, Dr Falk Pharma, Mirum Pharmaceuticals, and GlaxoSmithKline, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Biliary Cholangitis Treatment Market Valued at USD 1.2 Billion in 2023; Projected to Grow Significantly Through 2034 Driven by Anticipated Pipeline Drugs | DelveInsight

Dupuytren’s Disease Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Endo Pharma, Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences

 

DelveInsight’s “Dupuytren’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dupuytren’s Disease, historical and forecasted epidemiology as well as the Dupuytren’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Dupuytren’s Disease, offering comprehensive insights into the Dupuytren’s Disease revenue trends, prevalence, and treatment landscape. The report delves into key Dupuytren’s Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Dupuytren’s Disease therapies. Additionally, we cover the landscape of Dupuytren’s Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Dupuytren’s Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Dupuytren’s Disease space.

 

To Know in detail about the Dupuytren’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dupuytren’s Disease Market Forecast

 

Some of the key facts of the Dupuytren’s Disease Market Report:

  • The Dupuytren’s Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In July 2024, Connext has announced the successful first administration of CNT201, its therapeutic treatment for Dupuytren’s contracture, in patients. Dupuytren’s contracture is a debilitating condition where fibrosis develops in the fascia between the skin and tendons of the palm due to collagen accumulation, leading to permanently bent fingers and severely affecting the patient’s quality of life. At present, no definitive cure exists for this condition.

  • Key Dupuytren’s Disease Companies: Endo Pharmaceuticals/ Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences, and others

  • Key Dupuytren’s Disease Therapies: XIAFLEX (clostridium histolyticum), Anti-TNF drug adalimumab, VEN201, and others

  • The Dupuytren’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dupuytren’s Disease pipeline products will significantly revolutionize the Dupuytren’s Disease market dynamics.

  • A study conducted by Broekstra et al. (2022) identified 38,707 individuals with Dupuytren’s disease in a population-based dynamic cohort, indicating a point prevalence of 0.67% in 2013. Of the affected individuals, 64.6% were male and 35.3% were female.

  • According to a study by Sasaki et al. (2021) conducted in Japan, Dupuytren’s disease was identified in 44 individuals, reflecting an overall prevalence of 3.9%. Among men, the prevalence was 8.3%, while among women it was 1.3%. In participants over the age of 60, the prevalence increased to 7.7%—with 18.5% in men and 2.4% in women.

 

Dupuytren’s Disease Overview

Dupuytren’s Disease, also known as Dupuytren’s Contracture, is a progressive hand condition where the connective tissue (fascia) under the skin of the palm thickens and tightens. Over time, this can cause one or more fingers—most commonly the ring and little fingers—to bend inward toward the palm, making it difficult to fully straighten them.

It typically develops slowly and is more common in older adults, particularly males of Northern European descent. While it is usually painless, it can impact hand function and quality of life in advanced cases. Treatment options range from non-surgical therapies like injections to surgical procedures to release the contracted tissue.

 

Get a Free sample for the Dupuytren’s Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/dupuytrens-disease-market

 

Dupuytren’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Dupuytren’s Disease Epidemiology Segmentation:

The Dupuytren’s Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Dupuytren’s Disease

  • Prevalent Cases of Dupuytren’s Disease by severity

  • Gender-specific Prevalence of Dupuytren’s Disease

  • Diagnosed Cases of Episodic and Chronic Dupuytren’s Disease

 

Download the report to understand which factors are driving Dupuytren’s Disease epidemiology trends @ Dupuytren’s Disease Epidemiology Forecast

 

Dupuytren’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dupuytren’s Disease market or expected to get launched during the study period. The analysis covers Dupuytren’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dupuytren’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Dupuytren’s Disease Therapies and Key Companies

  • XIAFLEX (clostridium histolyticum): Endo Pharmaceuticals/ Asahi Kasei Pharma

  • Anti-TNF drug adalimumab: 180 Life Sciences

  • VEN201: Ventoux Biosciences

  • Adalimumab: 180 Life Sciences

 

Discover more about therapies set to grab major Dupuytren’s Disease market share @ Dupuytren’s Disease Treatment Landscape

 

Dupuytren’s Disease Market Drivers

  • Awareness of Dupuytren’s Disease has improved over time, leading to earlier diagnosis and intervention.

  • There have been advancements in both surgical and non-surgical treatment options for Dupuytren’s Disease, offering patients more choices for managing their condition.

 

Dupuytren’s Disease Market Barriers

  • There is growing interest in minimally invasive treatment options for Dupuytren’s Disease, which could offer reduced recovery times and improved patient outcomes.

  • Advancements in genetics and personalized medicine may lead to the development of tailored treatment approaches based on individual patient characteristics, potentially enhancing treatment efficacy

 

Scope of the Dupuytren’s Disease Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Dupuytren’s Disease Companies: Endo Pharmaceuticals/ Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences, and others

  • Key Dupuytren’s Disease Therapies: XIAFLEX (clostridium histolyticum), Anti-TNF drug adalimumab, VEN201, and others

  • Dupuytren’s Disease Therapeutic Assessment: Dupuytren’s Disease current marketed and Dupuytren’s Disease emerging therapies

  • Dupuytren’s Disease Market Dynamics: Dupuytren’s Disease market drivers and Dupuytren’s Disease market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Dupuytren’s Disease Unmet Needs, KOL’s views, Analyst’s views, Dupuytren’s Disease Market Access and Reimbursement

 

To know more about Dupuytren’s Disease companies working in the treatment market, visit @ Dupuytren’s Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Dupuytren’s Disease Market Report Introduction

2. Executive Summary for Dupuytren’s Disease

3. SWOT analysis of Dupuytren’s Disease

4. Dupuytren’s Disease Patient Share (%) Overview at a Glance

5. Dupuytren’s Disease Market Overview at a Glance

6. Dupuytren’s Disease Disease Background and Overview

7. Dupuytren’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Dupuytren’s Disease

9. Dupuytren’s Disease Current Treatment and Medical Practices

10. Dupuytren’s Disease Unmet Needs

11. Dupuytren’s Disease Emerging Therapies

12. Dupuytren’s Disease Market Outlook

13. Country-Wise Dupuytren’s Disease Market Analysis (2020–2034)

14. Dupuytren’s Disease Market Access and Reimbursement of Therapies

15. Dupuytren’s Disease Market Drivers

16. Dupuytren’s Disease Market Barriers

17. Dupuytren’s Disease Appendix

18. Dupuytren’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dupuytren’s Disease Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Endo Pharma, Asahi Kasei Pharma, 180 Life Sciences, Ventoux Biosciences